Pulse Biosciences (NASDAQ:PLSE) Insider Sells $472,600.00 in Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $23.63, for a total transaction of $472,600.00. Following the completion of the sale, the insider directly owned 43,298 shares of the company’s stock, valued at $1,023,131.74. This represents a 31.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Kevin Patrick Danahy also recently made the following trade(s):

• On Friday, February 13th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $23.53, for a total transaction of $470,600.00.
• On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $21.45, for a total transaction of $429,000.00.
• On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $25.20, for a total transaction of $504,000.00.

Pulse Biosciences Stock Performance

Shares of Pulse Biosciences stock opened at $25.08 on Friday. The company has a fifty day moving average of $16.21 and a 200 day moving average of $16.03. Pulse Biosciences, Inc has a fifty-two week low of $12.56 and a fifty-two week high of $26.30. The company has a market capitalization of $1.70 billion, a P/E ratio of -22.19 and a beta of 1.77.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06.

Analysts Set New Price Targets

Several analysts have recently commented on PLSE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Mizuho set a $30.00 price target on shares of Pulse Biosciences in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pulse Biosciences currently has an average rating of “Hold” and an average target price of $26.00.

Hedge Funds Weigh In On Pulse Biosciences

Hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. boosted its stake in Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after buying an additional 619 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after acquiring an additional 680 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Pulse Biosciences by 6.7% during the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after purchasing an additional 1,300 shares during the period. Westside Investment Management Inc. increased its holdings in Pulse Biosciences by 2.9% in the 4th quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock valued at $911,000 after purchasing an additional 1,886 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares during the period. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.